NO982252D0 - MÕlrettede, cytotoksiske antracyklin-analoger - Google Patents

MÕlrettede, cytotoksiske antracyklin-analoger

Info

Publication number
NO982252D0
NO982252D0 NO982252A NO982252A NO982252D0 NO 982252 D0 NO982252 D0 NO 982252D0 NO 982252 A NO982252 A NO 982252A NO 982252 A NO982252 A NO 982252A NO 982252 D0 NO982252 D0 NO 982252D0
Authority
NO
Norway
Prior art keywords
nitrogen
halo
carbon
och2
excess
Prior art date
Application number
NO982252A
Other languages
English (en)
Other versions
NO982252L (no
NO324035B1 (no
Inventor
Andrew V Schally
Attila A Nagy
Ren-Zhi Cai
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24247176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO982252(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of NO982252L publication Critical patent/NO982252L/no
Publication of NO982252D0 publication Critical patent/NO982252D0/no
Publication of NO324035B1 publication Critical patent/NO324035B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO19982252A 1995-11-27 1998-05-15 Antracyklin-analoger samt blandinger og anvendelser derav NO324035B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/562,652 US5843903A (en) 1995-11-27 1995-11-27 Targeted cytotoxic anthracycline analogs
PCT/EP1996/005029 WO1997019954A1 (en) 1995-11-27 1996-11-14 Targeted cytotoxic anthracycline analogs

Publications (3)

Publication Number Publication Date
NO982252L NO982252L (no) 1998-05-15
NO982252D0 true NO982252D0 (no) 1998-05-15
NO324035B1 NO324035B1 (no) 2007-07-30

Family

ID=24247176

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19982252A NO324035B1 (no) 1995-11-27 1998-05-15 Antracyklin-analoger samt blandinger og anvendelser derav
NO20051111A NO20051111L (no) 1995-11-27 2005-03-01 Fremgangsmate for omdanning av nitrogen i en primaer aminogruppe til nitrogen i en monoumettet, nitrogenholdig, heterocyklisk forbindelse

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20051111A NO20051111L (no) 1995-11-27 2005-03-01 Fremgangsmate for omdanning av nitrogen i en primaer aminogruppe til nitrogen i en monoumettet, nitrogenholdig, heterocyklisk forbindelse

Country Status (27)

Country Link
US (2) US5843903A (no)
EP (2) EP0863917B1 (no)
JP (2) JP3987575B2 (no)
KR (2) KR100467899B1 (no)
CN (2) CN1137136C (no)
AT (2) ATE251179T1 (no)
AU (1) AU709539B2 (no)
BR (1) BR9611647B1 (no)
CA (2) CA2238574C (no)
CZ (1) CZ297297B6 (no)
DE (2) DE69630233T2 (no)
DK (2) DK1384710T3 (no)
EA (1) EA001372B1 (no)
ES (2) ES2205067T3 (no)
HK (2) HK1017363A1 (no)
HU (1) HU229870B1 (no)
IL (3) IL119691A (no)
IS (2) IS2178B (no)
MX (1) MX9804119A (no)
NO (2) NO324035B1 (no)
NZ (1) NZ322054A (no)
PL (3) PL187230B1 (no)
PT (2) PT1384710E (no)
SK (2) SK284672B6 (no)
UA (1) UA67722C2 (no)
WO (1) WO1997019954A1 (no)
ZA (1) ZA969709B (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
EP1958961A3 (en) 1998-11-13 2008-09-03 Cyclacel Limited Transport Vectors
FR2786398B1 (fr) * 1998-11-30 2002-12-27 Synt Em Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
FR2786397B1 (fr) * 1998-11-30 2003-01-10 Synt Em Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
US6380161B1 (en) 1999-06-21 2002-04-30 Inkine Pharmaceutical Company, Inc. Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions
EP1235598A2 (en) * 1999-11-12 2002-09-04 Angiotech Pharmaceuticals, Inc. Compositions of a combination of radioactive therapy and cell-cycle inhibitors
DE60031793T2 (de) 1999-12-29 2007-08-23 Immunogen Inc., Cambridge Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
IL152466A0 (en) * 2000-04-26 2003-05-29 Mallinckrodt Inc RgD (Arg-Gly-Asp) COUPLED TO (NEURO) PEPTIDES
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
KR100420007B1 (ko) * 2001-04-25 2004-03-02 노영쇠 안트라사이클린 유도체 및 이를 포함하는 항암제
MXPA04002621A (es) 2001-09-21 2004-07-08 Univ Tulane Conjugados de analogos de somatostatina o bombesina para diagnostico o terapeuticos y usos de los mismos.
WO2003072754A2 (en) * 2002-02-27 2003-09-04 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
DE60331049D1 (de) 2002-03-01 2010-03-11 Univ Tulane Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden
US7544767B2 (en) 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
BR0306685A (pt) * 2002-05-21 2005-04-26 Daiichi Suntory Pharma Co Ltd Composição farmacêutica contendo grelina
CN100341589C (zh) 2002-05-24 2007-10-10 血管技术国际股份公司 用于涂覆医用植入物的组合物和方法
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
CA2633589A1 (en) 2002-09-26 2004-04-08 Angiotech International Ag Perivascular wraps
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US20050043215A1 (en) 2003-02-19 2005-02-24 Tamara Minko Complex drug delivery composition and method for treating cancer
US8709998B2 (en) 2003-04-22 2014-04-29 Ipsen Pharma S.A.S. Peptide vectors
AU2007221964B2 (en) * 2003-04-22 2008-12-11 Ipsen Pharma S.A.S. Peptide vectors
US7097993B2 (en) 2003-06-25 2006-08-29 Wisconsin Alumni Research Foundation Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity
WO2005086951A2 (en) * 2004-03-10 2005-09-22 Threshold Pharmaceuticals, Inc. Hypoxia-activated anti-cancer agents
US20070060534A1 (en) * 2005-06-30 2007-03-15 Threshold Pharmaceuticals, Inc. Anthracycline analogs
JP5340155B2 (ja) * 2006-09-06 2013-11-13 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 細胞結合分子を有するジソラゾールのコンジュゲート及びそれらの誘導体、新規ジソラゾール誘導体、それらの製法ならびに使用
EP1900742A1 (en) 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
WO2008100591A2 (en) * 2007-02-14 2008-08-21 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
ES2547552T3 (es) 2008-02-01 2015-10-07 Genentech, Inc. Metabolito de nemorrubicina y reactivos análogos, conjugados anticuerpo-fármaco y métodos
MX2010011079A (es) * 2008-04-11 2012-06-01 Tianjin Hemay Bio Tech Co Ltd Derivados antibioticos de antraquinona tetraciclica con alta actividad, proceso para preparar los mismos y uso de estos.
CN101555264B (zh) * 2008-04-11 2014-09-03 天津和美生物技术有限公司 具有高活性的四环蒽醌类抗生素的衍生物及其制备和应用
WO2010009124A2 (en) * 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
MX2011008774A (es) * 2009-02-20 2011-10-24 Ipsen Pharma Sas Conjugados citotoxicos que tienen un compuesto de unión de receptores de neuropeptidos y.
CN102050856B (zh) * 2009-11-03 2014-04-30 天津和美生物技术有限公司 具有高活性的表阿霉素的衍生物及其制备和应用
ES2533710T3 (es) 2010-12-02 2015-04-14 Nerviano Medical Sciences S.R.L. Proceso para la preparación de derivados de morfolinil antraciclina
CN105198966B (zh) * 2014-06-26 2019-06-21 中国人民解放军军事医学科学院毒物药物研究所 GnRH类似物-细胞毒分子缀合物、其制备方法及用途
CN106573077B (zh) 2014-06-30 2019-07-30 塔弗达治疗有限公司 靶向缀合物及其颗粒和制剂
EP3045540A1 (en) 2015-01-19 2016-07-20 Æterna Zentaris GmbH Enzymatic process for the regioselective manufacturing of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono esters
JP7057278B2 (ja) 2015-10-28 2022-04-19 ターベダ セラピューティクス インコーポレイテッド Ｓｓｔｒ標的化コンジュゲート及び粒子並びにその製剤
US10450340B2 (en) 2017-02-16 2019-10-22 Monopar Therapeutics Inc. 3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation
US20210402016A1 (en) * 2018-11-13 2021-12-30 Provincial Health Services Authority Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725350A (en) * 1972-04-26 1973-04-03 Commercial Soluents Corp Polymeric substances comprising the reaction product of melamine, aldehyde and oxazolidines
US4299822A (en) * 1980-06-09 1981-11-10 Sidney Farber Cancer Institute, Inc. N-Trifluoroacetyladriamycin-14-O-hemiglutarate and -hemiadipate and therapeutic compositions containing same
US4464529A (en) * 1982-07-20 1984-08-07 Sri International Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
FI102355B1 (fi) * 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
US5217955A (en) * 1989-09-15 1993-06-08 Biomeasure, Inc. Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin
US5304687A (en) * 1989-12-19 1994-04-19 Farmitalia Carlo Erba S.R.L. Morpholinyl derivatives of doxorubicin and process for their preparation
ATE143023T1 (de) * 1989-12-19 1996-10-15 Pharmacia Spa Chirale 1,5-diiodo-2-methoxy oder benzyloxy zwischenprodukte
DK0450480T3 (da) * 1990-04-06 1995-08-14 Univ Tulane Somatostatinaloger
ATE127476T1 (de) * 1990-04-06 1995-09-15 Univ Tulane Lhrh-analoge.
JP3169425B2 (ja) * 1992-03-27 2001-05-28 三共株式会社 アジドペンタンサイクリトール
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates

Also Published As

Publication number Publication date
HK1017363A1 (en) 1999-11-19
JP2007045845A (ja) 2007-02-22
IS2634B (is) 2010-06-15
CN1202903A (zh) 1998-12-23
IL134685A0 (en) 2001-04-30
JP2000502055A (ja) 2000-02-22
CA2238574C (en) 2004-10-19
CN1405127A (zh) 2003-03-26
SK284392B6 (sk) 2005-03-04
CZ297297B6 (cs) 2006-11-15
HK1052920A1 (en) 2003-10-03
IL134685A (en) 2002-12-01
EA001372B1 (ru) 2001-02-26
NO982252L (no) 1998-05-15
PL191781B1 (pl) 2006-07-31
KR100445754B1 (ko) 2004-12-08
NO324035B1 (no) 2007-07-30
PL188786B1 (pl) 2005-04-29
IS2178B (is) 2006-12-15
CN1137136C (zh) 2004-02-04
SK284672B6 (sk) 2005-08-04
EA199800492A1 (ru) 1998-12-24
IL119691A (en) 2002-02-10
PL187230B1 (pl) 2004-06-30
US6184374B1 (en) 2001-02-06
BR9611647A (pt) 1999-02-23
SK62898A3 (en) 1999-06-11
BR9611647B1 (pt) 2010-03-09
AU709539B2 (en) 1999-09-02
KR19990071672A (ko) 1999-09-27
KR20040037176A (ko) 2004-05-04
DE69630233D1 (de) 2003-11-06
PT1384710E (pt) 2008-10-08
EP1384710B1 (en) 2008-07-16
HK1052920B (zh) 2005-03-04
PT863917E (pt) 2004-02-27
NO20051111L (no) 2005-03-01
ES2310222T3 (es) 2009-01-01
HUP9903771A3 (en) 2000-07-28
AU7572296A (en) 1997-06-19
ATE401305T1 (de) 2008-08-15
ATE251179T1 (de) 2003-10-15
CN1166597C (zh) 2004-09-15
NZ322054A (en) 1999-04-29
UA67722C2 (en) 2004-07-15
DK1384710T3 (da) 2008-11-17
WO1997019954A1 (en) 1997-06-05
CA2471775C (en) 2008-01-29
IL119691A0 (en) 1997-02-18
JP4778405B2 (ja) 2011-09-21
HUP9903771A2 (hu) 2000-02-28
EP0863917B1 (en) 2003-10-01
PL326865A1 (en) 1998-10-26
DE69630233T2 (de) 2004-08-05
US5843903A (en) 1998-12-01
DK0863917T3 (da) 2004-01-19
EP1384710A1 (en) 2004-01-28
CA2238574A1 (en) 1997-06-05
JP3987575B2 (ja) 2007-10-10
EP0863917A1 (en) 1998-09-16
IS4734A (is) 1998-05-05
ZA969709B (en) 1997-08-25
ES2205067T3 (es) 2004-05-01
CA2471775A1 (en) 1997-06-05
DE69637604D1 (de) 2008-08-28
HU229870B1 (en) 2014-10-28
CZ135798A3 (cs) 1998-10-14
IS8567A (is) 2006-11-09
KR100467899B1 (ko) 2005-01-24
MX9804119A (es) 1998-09-30

Similar Documents

Publication Publication Date Title
DK0863917T3 (da) Målrettede cytotoksiske anthracyclin-analoger
SE9301911D0 (sv) New peptide derivatives
BR9813835A (pt) Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromboembólica
BR9917080A (pt) Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica
HU9600963D0 (en) Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
NZ302072A (en) 1,3-diamino propyl stereomeric derivatives and organic acid and inorganic salts of their amine intermediates in the preparation of retroviral protease inhibitors
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
MX9606494A (es) Compuestos organicos.
DK0941975T3 (da) Injiceringscement indeholdende korrosionshæmmere
TW333533B (en) Novel indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase
FI970452A (fi) Leukotrieenin biosynteesin estäminen ureajohdannaisten avulla
AR015458A1 (es) Compuestos de tetrahidrofurano, y composicion farmaceutica que lo contiene.
TH13531EX (th) สารต่อต้านเชื้อราชนิดไซคลิค เพพไทด์ และกรรมวิธีเตรียมสารเหล่านั้น
EP1210948A4 (en) DRUGS FOR NERVOUS DISEASES
HUP9902556A2 (hu) Szinergetikus herbicid készítmény és eljárás annak alkalmazására
YU58300A (sh) Postupak za dobijanje 3-aminoalkohola
ATE221897T1 (de) Inhibitoren der blutplättchen-aggregation, die c- terminale aminosäurereste mit aminergen seitenketten enthalten

Legal Events

Date Code Title Description
MK1K Patent expired